Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 111, Issue 3, 2011, Pages 54-57

  Govorin, N V ^a   Vasileva, A I ^a  

^a NONE

Author keywords

Antibodies to NR2 subunit of NMDA receptors; BDNF; Endothelin 1; GFAP; Haloperidol; Nitric oxide; Risperidone; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; RISPERIDONE; AUTOANTIBODY; BIOLOGICAL MARKER; NEUROLEPTIC AGENT; NR2B NMDA RECEPTOR;

ACUTE DISEASE; ARTICLE; BRAIN DEGENERATION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; HUMAN; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NEUROPROTECTION; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; THERAPY EFFECT; ADULT; BLOOD; FEMALE; IMMUNOLOGY; MALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; AUTOANTIBODIES; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HALOPERIDOL; HUMANS; MALE; NITRIC OXIDE; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79957878187     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Russian Source
2. Russian Source
3. Russian Source
4. Russian Source
5. Russian Source
6. Russian Source
7. Russian Source
8. Addington J., Young J., Addington D. Social outcome in early u psychosis. Psychological Medicine 2003; 33: 6: 1119-1124.
9. Angelucci F. et al. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiat 2005; 10: 4: 345-352.
10. Bai Y.M. et al. White matter abnormalities in schizophrenia patients with tardive dyskinesia: A diffusion tensor image study. Schizophrenia Research 2009; 109: 167-181.
11. Birchwood M. et al. Schizophrenia: early warning signs. Advances in Psychiatric Treatment 2000; 6: 93-101.
12. Bottlender R., Sato T., Moller H. Summer birth and deficit schizophrenia. Am J Psychiat 2003; 160: 594-595.
13. Cahn W. et al. Brain morphology in antipsychotic-naïve schizophrenia: a study of multiple brain structures. Arch Gen Psychiat 2002; 43: 66-72.
14. Cahn W. et al. Psychosis and brain volume changes during the first five years of schizophrenia. European Neuropsychopharmacology 2009; 19: 147-151.
15. Kahn R.S. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. The Lancet 2008; 371: 1085-1097.
16. Keefe R. Cognitive deficits in patients with schizophrenia: Effects and treatment. J Clin Psychiat 2007; 68: 8-13.
17. Lieberman J., Fenton W. Delayed detection of psychosis: causes consequences, and effect on public health. Am J Psychiat 2000; 157: 1127-1730.
18. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 1993; 9: 67-75.
19. Meltzer H.Y. Beyond control of acute exacerbation: enhancing effective and cognitive outcomes. CNS Spectr 2003; 11 (suppl. 2): 16-18.
20. Moscarelli M., Capri S. Schizophrenia: editors' introduction. Schizophrenia Bulletin 1991; 17: 3: 367-369.
21. Parikh U.H. et al. Recognizing and monitoring adverse events of secondgeneration antipsychotics in children and adolescents. Child Adolesc Psychiat Clin Am 2006; 15: 177-206.
22. Schooler N. et al. Risperidone and haloperidol in first episode psychosis: a long-term randomized trial. Am J Psychiat 2005; 162: 947-953.